Atlas Trials

Valneva Austria GmbH

44 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Valneva Austria GmbH

RecordFirmDate
VLA1553-403 Pregnancy Surveillance Study (NCT07414524)Valneva Austria GmbH2026-06-11
A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children (NCT07133178)Valneva Austria GmbH2026-02-06
Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil (NCT07347002)Valneva Austria GmbH2026-02-02
Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil (NCT07163845)Valneva Austria GmbH2025-09-22
A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV) (NCT06028841)Valneva Austria GmbH2024-04-10
Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults (NCT06334393)Valneva Austria GmbH2024-03-25
A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years (NCT06106581)Valneva Austria GmbH2023-12-18
COVID-19 Paediatric VLA2001-321 Study (NCT05298644)Valneva Austria GmbH2022-10-01
VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection (NCT05364242)Valneva Austria GmbH2022-05-09
COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222 (NCT04864561)Valneva Austria GmbH2021-04-26
Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553) (NCT04838444)Valneva Austria GmbH2021-04-02
Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults (NCT04786444)Valneva Austria GmbH2021-02-22
Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects (NCT04671017)Valneva Austria GmbH2020-12-16
Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults (NCT04546724)Valneva Austria GmbH2020-09-17
Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701 (NCT03576183)Valneva Austria GmbH2018-06-04
Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers (NCT03382964)Valneva Austria GmbH2018-03-05

Track Valneva Austria GmbH automatically

Every clearance here is in the API, with alerts when new ones post.